Below are links to view the quarterly newsletter Targeting Trends. If you would like to be added to the mailing list, please complete the information on our contact page.
Newsletter Highlights
- Funding Awarded (page 2)
- Retrograde Transport (page 5)
- Avidinylated-SAP (page 7)
[fivecol_one]Page 1 
Page 2 
Page 3 
Page 4 
Page 5 
Page 6 
Page 7 
Page 8 
[/fivecol_one][fivecol_four_last]
Biotinylated targeting: A viable option? (continued on page 6)
For the IB4-SAP illustration (Figure 1), our thanks to Christopher N. Honda, Ph.D., Associate Professor, Department of Neuroscience, University of Minnesota, 6-145 Jackson Hall, 321 Church Street, Minneapolis, MN 55455
Product information related to cover article: IB4-SAP (Cat. #IT-10), Biotinylation Service
Funding Awarded for SBIR Phase II Grant
Malia and Sam Kohls: Has it been a YEAR already?
Targeting Tickler
Targeting Talk: Retrograde Transport
- I’m interested in using SAP to eliminate cells through retrograde transport, like OX7-SAP and IB4-SAP have been used. Can you explain how retrograde transport works and if it is possible for this to work with dermorphin-SAP? What determines whether a targeted toxin will be able to be used in retrograde transport?
- If a targeted toxin cannot be used in retrograde transport, will it only kill cell bodies in the injection site or will it also kill terminals?
Targeting Teaser Winners from last issue
Targeting Tools: Featured Products
Targeting Teaser (Jumble)
[/fivecol_four_last]